Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888391 · ClinicalTrials.gov registry record · NA
12 Month Open Extension of TNS for ADHD.
A NA study of Attention Deficit Hyperactivity Disorder (ADHD), sponsored by James McGough.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03888391: Completed NA study of Attention Deficit Hyperactivity Disorder (ADHD), sponsored by James McGough.
NCT03888391 is a NA study of Attention Deficit Hyperactivity Disorder (ADHD) that has completed, run by James McGough. The registered enrollment target is 18 participants, below the 141-participant average among 18 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03888391, a NA study of Attention Deficit Hyperactivity Disorder (ADHD), has completed, sponsored by James McGough.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Participants who exhibit sufficient ADHD symptom improvement in a prior study of active TNS will be invited to continue in a 12-month extension study, designed to collect additional data on long-term response and tolerability and to provide participants ongoing clinical benefit from treatment.
Primary Outcome
A dimensional rating of ADHD symptoms, with scores ranging from 0 to 54, with higher scores signifying worse severity.
Conditions Studied
Interventions
- DEVICE Active TNS
Study Locations (1)
California
- UCLA Semel Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-12-01 |
| Est. Completion | 2018-05-30 |
| Phase | NA |
What the finished NCT03888391 record still lists
NCT03888391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 141-participant average among 18 other Attention Deficit Hyperactivity Disorder (ADHD) trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder (ADHD) appearing as the primary indexed condition, and to 1 intervention - of which Active TNS is the first listed.
NCT03888391 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03888391 about?
NCT03888391 is a clinical study titled "12 Month Open Extension of TNS for ADHD.". Participants who exhibit sufficient ADHD symptom improvement in a prior study of active TNS will be invited to continue in a 12-month extension study, designed to collect additional data on long-term response and tolerability and to provide participants ongoing clinical benefit from treatment.
What is the current status of trial NCT03888391?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2014-12-01. Estimated completion is 2018-05-30.
What conditions does trial NCT03888391 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder (ADHD).
What interventions are being tested in trial NCT03888391?
The interventions under investigation include: Active TNS (DEVICE).
Who is sponsoring clinical trial NCT03888391?
This trial is sponsored by James McGough, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03888391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder (ADHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03888391's enrollment target sits among peer trials
18 19th of 18 the lowest of 18 other Attention Deficit Hyperactivity Disorder (ADHD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder (ADHD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving ADHD Teen Driving - Virtual Reality
RECRUITING · NA
-
Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD
RECRUITING · NA
-
L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD
RECRUITING · NA
-
Organizational Skill Training (OST) in Schools
COMPLETED · NA
-
Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program)
COMPLETED · NA
-
The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI